Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCR Followed by Alemtuzumab in Relapsed/Refractory CLL
NCT00074282Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Apr 2005
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Eastern Cooperative Oncology Group. Started Apr 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00074282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074282.